Al-Saeedi Mohammed, Barout Muhammed H, Probst Pascal, Khajeh Elias, Weiss Karl Heinz, Diener Markus K, Mehrabi Arianeb
Department of General, Visceral, and Transplantation Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany.
The Study Center of the German Surgical Society (SDGC), University of Heidelberg, Im Neuenheimer Feld 130/3, 69120, Heidelberg, Germany.
Langenbecks Arch Surg. 2018 Nov;403(7):825-836. doi: 10.1007/s00423-018-1720-z. Epub 2018 Oct 22.
This review investigated survival and alcoholic relapse following liver transplantation (LT) in patients with severe acute alcoholic hepatitis (AH) without 6 months of alcohol abstinence.
All studies comparing acute AH patients undergoing LT with a control group were included. CENTRAL, MEDLINE, and Web of Science databases were searched. Survival benefits or odds ratios (OR) and 95% confidence intervals (CI) were assessed by meta-analyses using a random effects model. The study was registered in PROSPERO (CRD42017057971). According to the search results, two separate meta-analyses were performed: meta-analysis A compared early LT with medical therapy alone in patients with severe AH that were not responding to medical therapy and meta-analysis B compared LT outcome in patients with AH and chronic alcoholic cirrhosis (AC).
The search yielded 2232 articles. Eight studies were included in the two meta-analyses-two studies in meta-analysis A and six studies in meta-analysis B. The two studies (n = 70) included in meta-analysis A revealed that 1-year patient survival was significantly higher in the LT group compared with the medical therapy-alone group (survival benefit, 15.88; 95% CI, 3.98-63.35; p < 0.0001). The six studies in meta-analysis B (including 1091 patients) showed that 1-year (survival benefit, 1.65; 95% CI, 0.95-2.89; p = 0.08), 3-year (survival benefit, 1.31; 95% CI, 0.79-2.18; p = 0.30), and 5-year survival (survival benefit, 1.54; 95% CI, 0.92-2.56; p = 0.10) were not significantly different between AH and AC groups. There was no significant difference in the rate of alcohol relapse between the groups (OR, 1.26; 95% CI, 0.53-2.96; p = 0.60).
Early LT is a life-saving treatment for AH patients that do not respond to medical therapy. The chance of alcohol relapse after LT is not increased in selected patients.
本综述调查了未戒酒6个月的重症急性酒精性肝炎(AH)患者肝移植(LT)后的生存率及酒精复饮情况。
纳入所有将接受LT的急性AH患者与对照组进行比较的研究。检索CENTRAL、MEDLINE和Web of Science数据库。采用随机效应模型通过荟萃分析评估生存获益或比值比(OR)及95%置信区间(CI)。本研究已在国际前瞻性系统评价注册库(PROSPERO,注册号:CRD42017057971)登记。根据检索结果,进行了两项独立的荟萃分析:荟萃分析A将重症AH且对药物治疗无反应的患者中早期LT与单纯药物治疗进行比较;荟萃分析B比较AH和慢性酒精性肝硬化(AC)患者的LT结局。
检索共获得2232篇文章。两项荟萃分析纳入了8项研究——荟萃分析A中有2项研究,荟萃分析B中有6项研究。荟萃分析A纳入的两项研究(n = 70)显示,LT组1年患者生存率显著高于单纯药物治疗组(生存获益,15.88;95% CI,3.98 - 63.35;p < 0.0001)。荟萃分析B中的6项研究(包括1091例患者)显示,AH组和AC组之间1年(生存获益,1.65;95% CI,0.95 - 2.89;p = 0.08)、3年(生存获益,1.31;95% CI,0.79 - 2.18;p = 0.30)和5年生存率(生存获益,1.54;95% CI,0.92 - 2.56;p = 0.10)无显著差异。两组间酒精复饮率无显著差异(OR,1.26;95% CI,0.53 - 2.96;p = 0.60)。
早期LT是对药物治疗无反应的AH患者的救命治疗方法。特定患者LT后酒精复饮的几率并未增加。